Torasemide extended release - Sarfez Pharmaceuticals

Drug Profile

Torasemide extended release - Sarfez Pharmaceuticals

Alternative Names: Torsemide extended release - Sarfez Pharmaceuticals

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sarfez Pharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfonamides
  • Mechanism of Action Loop diuretics; Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Oedema

Most Recent Events

  • 14 Jul 2017 Sarfez Pharmaceuticals plans a phase I food-drug interaction trial in Healthy volunteers in India (NCT03215875)
  • 14 Jun 2017 Phase-I clinical trials in Oedema (In volunteers) in India (PO) (NCT03214874)
  • 12 Nov 2013 Clinical trials in Oedema (In volunteers) (PO) prior to November 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top